Prof Philippe Lambin and his colleagues have received a prestigious technology transfer “Eurostar” subsidy in collaboration with a belgian pharmaceutical company. The objective of the project is to develop in multifactorial Biomarkers-based Companion Predictive Model for hypoxia-activated prodrugs (HAP). This will be done by integrating and validating distinct HAP-related biomarkers for: hypoxia, activity of nitroreductases, cellular sensitivity, and pharmacokinetic features. Watch the animation https://youtu.be/LjbfbQ_OON8. The project received a high score and was ranked in the top 8% of the European projects out of 380 submissions.